Pharmaceutical

Donanemab: FDA AdCom will put spotlight on tau enrolmen...

Lilly says that the FDA wants to look closer at efficacy implications of the Pha...

Early AMR pipeline looks beyond traditional antibiotics

Different therapeutic approaches against antibiotic-resistant bacteria were high...

Nouscom extends Series C round to $82m for cancer vacci...

Nouscom is part of a cancer vaccine landscape that has recently jump-started fol...

Keytruda combination treatment for NSCLC falls short in...

The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treat...

Molecular glues are the latest craze in pharma research...

Deals involving research into molecular glues have skyrocketed this year as big ...

NVIDIA doubles down on AI in healthcare with drug disco...

In addition to drug discovery deals, NVIDIA also announced partnerships with J&J...

Eli Lilly’s partnership with Amazon to boost presence i...

Eli Lilly's LillyDirect allows for online consultations and prescriptions, and A...

Asieris showcases Phase III win in treating precancerou...

Asieris presented positive Phase III results at the 2024 Society of Gynecologic ...

AstraZeneca to acquire radioconjugate biotech Fusion in...

As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a...

China NMPA approves KeChow’s tunlametinib for melanoma

The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating...

Microsoft and NVIDIA expand collaboration in healthcare...

Microsoft has announced plans to broaden its partnership with NVIDIA to leverage...

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics ...

Is HIV-TB coinfection treatment entering a new frontier?

TB is the leading determiner of death in patients with HIV, yet while new drug r...

Biden’s administration initiative aims to advance women...

The new initiative aims to spur innovation and mobilisation of sectors to drive ...

FDA approves Madrigal’s Rezdiffra as the first NASH the...

Madrigal’s Rezdiffra received an accelerated approval as a treatment for noncirr...